Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 05, 2015 09:01 ET | Source: Agios Pharmaceuticals, Inc.

Agios Announces Data from Ongoing Phase 1 Trial of AG-120 Showing Durable Responses in Patients with Advanced Hematologic Malignancies

- Patients on Study for up to 14.1 Months with a Median Response Duration of 5.6 Months - - Four Phase 1 Expansion Cohorts Enrolling; Planned Global Registration-enabling Phase 3 Study On Track...
November 08, 2015 08:01 ET | Source: Agios Pharmaceuticals, Inc.

Agios Announces Data from Dose-Escalation Phase 1 Study of AG-120 in Patients with IDH1 Mutant Positive Advanced Solid Tumors

- Safety Profile Confirmed; Signs of Clinical and Biological Activity Observed; Recommended Phase 2 Dose Selected - - Phase 1 Expansion Cohorts for Patients with IDH1 Mutant Positive Glioma,...
November 05, 2015 09:47 ET | Source: Agios Pharmaceuticals, Inc.

Agios to Present New Data From Lead Programs at the 2015 ASH Annual Meeting

- New Safety and Efficacy Data from Ongoing Studies of AG-221 and AG-120 to be Highlighted in Oral and Poster Presentations - - Posters to Feature Pharmacokinetics and Pharmacodynamics Data for...
November 05, 2015 07:01 ET | Source: Agios Pharmaceuticals, Inc.

Agios Reports Third Quarter 2015 Financial Results

– New AG-221 and AG-120 Data in Solid Tumors and Hematologic Malignancies to be Presented at AACR-NCI-EORTC and ASH Annual Meeting – – R&D Day Highlights Included Initiation...
November 03, 2015 07:30 ET | Source: Agios Pharmaceuticals, Inc.

Agios to Present at Credit Suisse 24th Annual Healthcare Conference on Tuesday, November 10

CAMBRIDGE, Mass., Nov. 3, 2015 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced that the...
October 29, 2015 07:30 ET | Source: Agios Pharmaceuticals, Inc.

Agios to Webcast Conference Call of Third Quarter 2015 Financial Results on November 5, 2015

CAMBRIDGE, Mass., Oct. 29, 2015 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced that...
October 26, 2015 16:35 ET | Source: Agios Pharmaceuticals, Inc.

Agios to Present Clinical Data from Ongoing AG-120 Phase 1 Trial in Advanced Solid Tumors at AACR-NCI-EORTC

CAMBRIDGE, Mass., Oct. 26, 2015 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced that the...
October 16, 2015 07:01 ET | Source: Agios Pharmaceuticals, Inc.

Agios Outlines Key Clinical Development & Research Strategies

- Phase 3 Study of AG-221 in Relapsed/Refractory IDH2 Mutant Acute Myeloid Leukemia (IDHENTIFY) Initiated - - Frontline Combination Development Strategy for AG-221 and AG-120 Announced - -...
October 08, 2015 07:30 ET | Source: Agios Pharmaceuticals, Inc.

Agios to Webcast R&D Day on October 16, 2015

CAMBRIDGE, Mass., Oct. 8, 2015 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced that the...
September 23, 2015 16:01 ET | Source: Agios Pharmaceuticals, Inc.

Agios to Present at Leerink Partners Rare Disease Roundtable

CAMBRIDGE, Mass., Sept. 23, 2015 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced that the...